AI assistant could sharpen eye injection choices

NCT ID NCT07328776

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tests an artificial intelligence system called QiLin that helps doctors decide when to give anti-VEGF injections for retinal diseases like wet AMD, DME, and RVO. About 200 patients who have completed initial treatment will be randomly assigned to have their doctor use the AI or not. The main goal is to see if AI-assisted decisions match expert recommendations more often than doctor-only decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
QiLin artificial intelligence system
What this could lead to
If successful, this AI tool could help doctors make more accurate decisions about anti-VEGF injections, potentially improving outcomes for patients with retinal diseases.
What could go wrong
This is an early-stage trial with 200 participants. The AI may not perform as well in real-world settings as in lab tests, and its benefit over standard care is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shanghai general hospital

    Shanghai, China

  • Shanghai general hospital, Shanghai Jiao Tong University, Shanghai, 200080

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.